Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on August 9, 2021. The filing serves to announce the Company's financial results for the second quarter ended June 30, 2021. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol "CARA."
Key Financial Metrics
The provided text is a cover page and index for the 8-K filing. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this document.
- Revenue, Profit, Cash Flow, Margins: The filing text does not provide a clear value for these metrics.
- Debt and Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. It only indicates that results for the quarter ended June 30, 2021, were announced.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained in the referenced press release (Exhibit 99.1), which is incorporated by reference but not reproduced in the provided text.
Important Facts for Investor Verification
- Verify the specific financial results (revenue, net loss, cash position) in the press release dated August 9, 2021, referenced as Exhibit 99.1.
- Confirm the Company's name is Cara Therapeutics, Inc., as the input metadata incorrectly listed "Tvardi Therapeutics, Inc."
- Note that the information in this 8-K is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
- Review the full press release for any updates on clinical trials or product development, which are typical for this biopharmaceutical company.